Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du Sells 50,000 Shares

Zai Lab Limited (NASDAQ:ZLAB) CEO Ying Du sold 50,000 shares of Zai Lab stock in a transaction on Friday, February 28th. The stock was sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the sale, the chief executive officer now directly owns 494,117 shares in the company, valued at approximately $17,032,212.99. This trade represents a 9.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ying Du also recently made the following trade(s):

• On Monday, March 3rd, Ying Du sold 50,000 shares of Zai Lab stock. The shares were sold at an average price of $32.44, for a total transaction of $1,622,000.00.

Zai Lab Stock Performance

Shares of NASDAQ ZLAB traded up $2.27 during trading on Tuesday, hitting $34.00. 1,927,970 shares of the company were exchanged, compared to its average volume of 914,397. The company has a fifty day moving average price of $27.77 and a 200-day moving average price of $26.06. The firm has a market capitalization of $3.72 billion, a PE ratio of -12.27 and a beta of 1.02. Zai Lab Limited has a 12-month low of $13.48 and a 12-month high of $36.60.

Zai Lab (NASDAQ:ZLAB) last issued its earnings results on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $109.07 million for the quarter, compared to analysts’ expectations of $110.15 million. Research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZLAB has been the subject of several research reports. Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a research note on Wednesday, February 5th. Bank of America restated a “neutral” rating and issued a $36.10 price target (up from $29.00) on shares of Zai Lab in a research report on Monday.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ZLAB. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Zai Lab by 26.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after purchasing an additional 125,532 shares during the last quarter. Algert Global LLC purchased a new stake in Zai Lab in the 3rd quarter valued at about $1,666,000. Daiwa Securities Group Inc. lifted its position in Zai Lab by 4,851.8% in the third quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after buying an additional 9,364 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Zai Lab by 3.3% during the third quarter. The Manufacturers Life Insurance Company now owns 121,084 shares of the company’s stock worth $2,923,000 after buying an additional 3,860 shares during the period. Finally, PEAK6 Investments LLC acquired a new stake in shares of Zai Lab during the third quarter valued at about $386,000. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.